CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.
Fennell BJ, McDonnell B, Tam AS, Chang L, Steven J, Broadbent ID, Gao H, Kieras E, Alley J, Luxenberg D, Edmonds J, Fitz LJ, Miao W, Whitters MJ, Medley QG, Guo YJ, Darmanin-Sheehan A, Autin B, Shúilleabháin DN, Cummins E, King A, Krebs MR, Grace C, Hickling TP, Boisvert A, Zhong X, McKenna M, Francis C, Olland S, Bloom L, Paulsen J, Somers W, Jensen A, Lin L, Finlay WJ, Cunningham O.
Fennell BJ, et al. Among authors: edmonds j.
MAbs. 2013 Nov-Dec;5(6):882-95. doi: 10.4161/mabs.26201. Epub 2013 Aug 21.
MAbs. 2013.
PMID: 23995618
Free PMC article.